Home Companies Catalysts Deep Dives
Qulipta atogepant APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaNeurology
Launch2021-09-28
US LOE2034-09-28
Peak Sales Est$2000M
Formulations[{"id":"qulipta-po","doses":"10mg, 30mg, 60mg","route":"PO","setting":"PATIENT_SELF","frequency":"On
Companies
ABBV (ORIGINATOR)100%
Mechanism: CGRP antagonist
Expert: Small molecule or antibody antagonizing calcitonin gene-related peptide (CGRP) or its receptor, blocking migraine signaling.
Everyday: Blocks a protein that causes migraines, preventing or stopping headache attacks.
Targets: ["CGRP"]
Revenue History
PeriodRevenue ($M)
2025$1,157M
Programs (1)
IndicationStageKey StudyRegional Status
Ep MigraineAPPROVEDADVANCE[{"stage":"APPROVED","region":"US","approval_date":"2021-09-28"}]
Notes
First oral CGRP antagonist for migraine prevention. Daily dosing. Growing rapidly in preventive migraine.
Data from Supabase · Updated 2026-03-24